CSL just posted its first-ever annual loss of $2.6 billion, a sharp reversal from last year’s $3 billion profit, as revenue dipped to $15.8 billion amid writedowns on its struggling Vifor kidney and iron treatments. The company’s “reset year” includes restructuring costs and lower vaccine demand, while the 2022 Vifor acquisition continues to underperform against generic competition. Surprisingly, shares jumped 16%—viewed by markets as a necessary cleanup for future growth. Interim CEO Gordon Naylor says groundwork is being laid, but analysts caution that full recovery may take longer, with Vifor still dragging performance. Investors will need patience as CSL searches for a permanent CEO and rebuilds toward its former peak.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
